Free Trial

McKesson (MCK) Stock Forecast & Price Target

$558.24
+9.72 (+1.77%)
(As of 08/21/2024 ET)

McKesson - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 15 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a hold rating, and 13 have given a buy rating for MCK.

Consensus Price Target

$620.29
11.11% Upside
High Forecast$671.00
Average Forecast$620.29
Low Forecast$545.00

According to the 15 analysts' twelve-month price targets for McKesson, the average price target is $620.29. The highest price target for MCK is $671.00, while the lowest price target for MCK is $545.00. The average price target represents a forecasted upside of 11.11% from the current price of $558.24.

TypeCurrent Forecast
8/23/23 to 8/22/24
1 Month Ago
7/24/23 to 7/23/24
3 Months Ago
5/25/23 to 5/24/24
1 Year Ago
8/23/22 to 8/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
14 Buy rating(s)
13 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$620.29$599.33$571.47$452.33
Forecasted Upside11.11% Upside10.38% Upside9.94% Upside13.81% Upside
Get McKesson Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

McKesson Stock vs. The Competition

TypeMcKessonMedical CompaniesS&P 500
Consensus Rating Score
2.87
2.75
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside11.11% Upside5,591.80% Upside8.74% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/21/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$656.00 ➝ $661.00+19.54%
8/8/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$596.00 ➝ $616.00+12.78%
8/8/2024Mizuho
2 of 5 stars
 Boost TargetNeutral$540.00 ➝ $570.00+4.58%
8/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$660.00 ➝ $630.00+2.02%
8/8/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$694.00 ➝ $671.00+8.66%
7/19/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$620.00 ➝ $670.00+15.32%
6/25/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$590.00 ➝ $670.00+10.23%
6/24/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$570.00 ➝ $670.00+11.10%
5/9/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$547.00 ➝ $545.00-1.45%
5/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$502.00 ➝ $551.00-0.41%
5/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$563.00 ➝ $652.00+19.74%
5/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$620.00 ➝ $630.00+14.00%
4/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$522.00 ➝ $548.00+4.21%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$600.00+16.23%
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$450.00 ➝ $485.00+11.71%
5/9/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
11/2/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$384.00 ➝ $416.00+5.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:31 AM ET.

MCK Forecast - Frequently Asked Questions

What is McKesson's forecast for 2024?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $620.29, with a high forecast of $671.00 and a low forecast of $545.00.

Should I buy or sell McKesson stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCK shares.

Does McKesson's stock price have much upside?

According to analysts, McKesson's stock has a predicted upside of 9.69% based on their 12-month stock forecasts.

What analysts cover McKesson?

McKesson has been rated by research analysts at Argus, Bank of America, Barclays, Citigroup, Evercore ISI, JPMorgan Chase & Co., Mizuho, and Robert W. Baird in the past 90 days.

Do Wall Street analysts like McKesson more than its competitors?

Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.87 while the average consensus rating score for "medical" companies is 2.75. Learn more on how MCK compares to other companies.


This page (NYSE:MCK) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners